Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 34 EU countries

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Additional governmental funding for cancer care in Denmark

30 Nov 2023

The Danish government granted additional funding of 300 million DKK for the extraordinary and urgent strengthening of cancer care in 2024. In November 2023, the Danish Regions and the government signed an agreement comprising the distribution of that funding. 

  • The block grants of 281 million DKK will be provided to regions to strengthen cooperation, including treatment abroad, expansion and simplification of subsidies for dental care (as a consequence of cancer treatment), implementation of new patient counseling, and a special unit focusing on life-threatening diseases;
  • The remaining 19 million DKK will be set aside for other initiatives, i.e., for an enhanced model for monitoring the maximum waiting times in the cancer field and a pilot study of a national screening program for lung cancer.

Furthermore, from 2025, the government has set permanent annual funding of 600 million DKK for Cancer Plan V (Kræftplan V), which the Danish Health Authority will develop. The plan is expected to be published in Autumn 2024 and is focused on the following: prevention, utilization of novel technologies, such as AI, for early diagnosis of cancer, and strengthened efforts for late sequelae and palliation.

See the full details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.